The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial
Open accessAbstract
Background Safety and efficacy have been shown in a phase 1 dose-escalation study involving a unilateral subretinal injection of a recombinant adeno-associated virus (AAV) vector containing the RPE65 gene (AAV2-hRPE65v2) in individuals with inherited retinal dystrophy caused by RPE65 mutations. This finding, along with the bilateral nature of the disease and intended use in treatment, prompted us to determine the safety of administration of AAV2-hRPE65v2 to the contralateral eye in patients enrolled in the phase 1 study.Methods In this follow-on phase 1 trial, one dose of AAV2-hRPE65v2 (1.5 × 10(11) vector genomes) in a total volume of 300 μL was subretinally injected into the contralateral, previously uninjected, eyes of 11 children and adults (aged 11-46 years at second administration) with inherited retinal dystrophy caused by RPE65 mutations, 1.71-4.58 years after the initial subretinal injection. We assessed safety, immune response, retinal and visual function, functional vision, and activation of the visual cortex from baseline until 3 year follow-up, with observations ongoing. This study is registered with ClinicalTrials.gov, number NCT01208389.Findings No adverse events related to the AAV were reported, and those related to the procedure were mostly mild (dellen formation in three patients and cataracts in two). One patient developed bacterial endophthalmitis and was excluded from analyses. We noted improvements in efficacy outcomes in most patients without significant immunogenicity. Compared with baseline, pooled analysis of ten participants showed improvements in mean mobility and full-field light sensitivity in the injected eye by day 30 that persisted to year 3 (mobility p=0.0003, white light full-field sensitivity p<0.0001), but no significant change was seen in the previously injected eyes over the same time period (mobility p=0.7398, white light full-field sensitivity p=0.6709). Changes in visual acuity from baseline to year 3 were not significant in pooled analysis in the second eyes or the previously injected eyes (p>0.49 for all time-points compared with baseline).Interpretation To our knowledge, AAV2-hRPE65v2 is the first successful gene therapy administered to the contralateral eye. The results highlight the use of several outcome measures and help to delineate the variables that contribute to maximal benefit from gene augmentation therapy in this disease.Funding Center for Cellular and Molecular Therapeutics at The Children's Hospital of Philadelphia, Spark Therapeutics, US National Institutes of Health, Foundation Fighting Blindness, Institute for Translational Medicine and Therapeutics, Research to Prevent Blindness, Center for Advanced Retinal and Ocular Therapeutics, Mackall Foundation Trust, F M Kirby Foundation, and The Research Foundation-Flanders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the presence of pre-existing neutralizing antibodies to AAV does not appear to correlate with a higher risk of retinal inflammation or reduced therapeutic efficacy, provided that the AAV vector is delivered via the subretinal route.27, 28, 29”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Apart from one participant who unfortunately devel oped culture-positive bacterial endophthalmitis after surgery, no par ticipants demonstrated intraocular inflammation or CRA within three years of second eye treatment.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bennett et al., 2016
Experimental — accuracy not yet measuredIn the citing paper
“Furthermore, in the clinical setting, ocular and intrathecal AAV gene delivery have shown limited transgene-related immune responses, possibly due to their compartmentation and reduced antigen presentation [16, 132, 133].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [133]
In the citing paper
“Phase I to III clinical trials for Luxturna have consistently demonstrated its ability to bring about sustained improvements in low luminance vision in otherwise blind patients [Maguire 2009; Bennett 2016; Russell 2017].”
From Correcting visual loss by genetics and prosthetics (2020) · cites this paper as Bennett 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Self-citationEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Self-citationHauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
Self-citationLong-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., Georgiadis, A., Mowat, F. M., Beattie, S. G., Gardner, P. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414221 · Cited by 743
Holladay, J. T. (2004) · Journal of Cataract & Refractive Surgery · doi:10.1016/j.jcrs.2004.01.014 · Cited by 688
Cideciyan, A. V., Alemán, T. S., Boye, S. L., Schwartz, S., Kaushal, S., Román, A. J., Pang, J., Sumaroka, A., Windsor, E. A. M., Wilson, J. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807027105 · Cited by 674
Jacobson, S. G. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.298 · Cited by 639
Research works printed but not linked: 1
- Amado, 2010, Safety and efficacy of subretinal re-administration of an AAV2 vector in large animal models: implications for studies in humans, Sci Transl Med, 2, 21ra16
Cited by
Sorted by citations
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
Self-citationChan, K. Y., Jang, M. J., Yoo, B. B., Greenbaum, A., Ravi, N., Wu, W.-L., Sánchez-Guardado, L., Lois, C., Mazmanian, S. K., Deverman, B. E., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4593 · Cited by 1,578
Dunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018) · Science · doi:10.1126/science.aan4672 · Cited by 1,410
Self-citationThe current landscape of nucleic acid therapeutics
Kulkarni, J. A., Witzigmann, D., Thomson, S. B., Chen, S., Leavitt, B. R., Cullis, P. R., & van der Meel, R. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00898-0 · Cited by 1,371
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362
Gene therapy clinical trials worldwide to 2012 – an update
Ginn, S. L., Alexander, I. E., Edelstein, M. L., Abedi, M. R., & Wixon, J. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2698 · Cited by 1,187
Gene therapy clinical trials worldwide to 2017: An update
Ginn, S. L., Amaya, A. K., Alexander, I. E., Edelstein, M., & Abedi, M. R. (2018) · The Journal of Gene Medicine · doi:10.1002/jgm.3015 · Cited by 903
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
Self-citationBrain-Derived Neurotrophic Factor in Alzheimer’s Disease and Its Pharmaceutical Potential
Gao, L., Zhang, Y., Sterling, K., & Song, W. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00279-0 · Cited by 606
Entering the Modern Era of Gene Therapy
Anguela, X. M., & High, K. A. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-012017-043332 · Cited by 494
Self-citationDias, M. F., Joo, K., Kemp, J. A., Fialho, S. L., Silva‐Cunha, A., Woo, S. J., & Kwon, Y. J. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.10.004 · Cited by 437
Maguire, A. M., Russell, S., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., Marshall, K. A., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.06.017 · Cited by 409
Self-citationCehajic-Kapetanovic, J., Xue, K., Martinez-Fernandez de la Camara, C., Nanda, A., Davies, A., Wood, L. J., Salvetti, A. P., Fischer, M. D., Aylward, J. W., Barnard, A. R., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0763-1 · Cited by 368
Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders
Shahryari, A., Jazi, M. S., Mohammadi, S., Nikoo, H. R., Nazari, Z., Hosseini, E. S., Burtscher, I., Mowla, S. J., & Lickert, H. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00868 · Cited by 271
Inherited Retinal Degenerations: Current Landscape and Knowledge Gaps
Duncan, J., Pierce, E., Laster, A., Daiger, S. P., Birch, D., Ash, J., Iannaccone, A., Flannery, J., Sahel, J., Zack, D., et al. (2018) · Translational Vision Science & Technology · doi:10.1167/tvst.7.4.6 · Cited by 228
Self-citationBucher, K., Rodríguez-Bocanegra, E., Dauletbekov, D., & Fischer, M. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100915 · Cited by 242
Gene Editing for CEP290 -Associated Retinal Degeneration
Pierce, E. A., Aleman, T. S., Jayasundera, K. T., Ashimatey, B. S., Kim, K., Rashid, A., Jaskolka, M. C., Myers, R. L., Lam, B. L., Bailey, S. T., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309915 · Cited by 237
Self-citationStemming retinal regeneration with pluripotent stem cells
Jin, Z., Gao, M.-L., Deng, W.-L., Wu, K., Sugita, S., Mandai, M., & Takahashi, M. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.11.003 · Cited by 221
Mingozzi, F., & High, K. A. (2017) · Annual Review of Virology · doi:10.1146/annurev-virology-101416-041936 · Cited by 206
Self-citationStingl, K., Schippert, R., Bartz-Schmidt, K. U., Besch, D., Cottriall, C. L., Edwards, T. L., Gekeler, F., Greppmaier, U., Kiel, K., Koitschev, A., et al. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00445 · Cited by 198
Biomanufacturing for clinically advanced cell therapies
Aijaz, A., Li, M., Smith, D. W., Khong, D., LeBlon, C. E., Fenton, O. S., Olabisi, R. M., Libutti, S. K., Tischfield, J. A., Maus, M. V., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0246-6 · Cited by 198
Technique of retinal gene therapy: delivery of viral vector into the subretinal space
Xue, K., Groppe, M., Salvetti, A. P., & MacLaren, R. E. (2017) · Eye · doi:10.1038/eye.2017.158 · Cited by 191
Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy
Maguire, A. M., Bennett, J., Aleman, E. M., Leroy, B. P., & Alemán, T. S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.11.029 · Cited by 189
Self-citationAl-Zaidy, S. A., & Mendell, J. R. (2019) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2019.06.007 · Cited by 189
Novel mobility test to assess functional vision in patients with inherited retinal dystrophies
Chung, D. C., McCague, S., Yu, Z., Thill, S., DiStefano‐Pappas, J., Bennett, J., Cross, D., Marshall, K. A., Wellman, J. A., & High, K. A. (2017) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.13022 · Cited by 172
Self-citationChoroideremia gene therapy phase 2 clinical trial: 24-month results
Lam, B. L., Davis, J. L., Gregori, N. Z., MacLaren, R. E., Girach, A., Verriotto, J. D., Rodriguez, B., Rosa, P. R., Zhang, X., & Feuer, W. J. (2019) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.09.012 · Cited by 161
Dulla, K., Aguilà, M., Lane, A., Jovanovic, K., Parfitt, D. A., Schulkens, I. A. E., Chan, H. L., Schmidt, I., Beumer, W., Vorthoren, L., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.07.010 · Cited by 166
Kaufmann, P., Pariser, A., & Austin, C. P. (2018) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-018-0936-x · Cited by 169
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
“Furthermore, in the clinical setting, ocular and intrathecal AAV gene delivery have shown limited transgene-related immune responses, possibly due to their compartmentation and reduced antigen presentation [16, 132, 133].”
BackgroundInjectable hydrogels for ophthalmic applications
Wang, K., & Han, Z. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.10.031 · Cited by 158
A New Promoter Allows Optogenetic Vision Restoration with Enhanced Sensitivity in Macaque Retina
Chaffiol, A., Caplette, R., Jaillard, C., Brazhnikova, E., Desrosiers, M., Dubus, É., Duhamel, L., Macé, É., Marre, O., Benoit, P., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.07.011 · Cited by 153
Ju, W., Perkins, G. A., Keun-young Kim, A., Bastola, T., Choi, W.-Y., & Choi, S. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101136 · Cited by 152
Evaluation of Dose and Safety of AAV7m8 and AAV8BP2 in the Non-Human Primate Retina
Ramachandran, P. S., Lee, V., Wei, Z., Song, J. Y., Casal, G., Cronin, T., Willett, K., Huckfeldt, R., Morgan, J. I. W., Aleman, T. S., et al. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.111 · Cited by 147
Self-citationAntisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations
Dulla, K., Slijkerman, R. W. N., van Diepen, H. C., Albert, S., Dona, M., Beumer, W., Turunen, J. J., Chan, H. L., Schulkens, I. A. E., Vorthoren, L., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.024 · Cited by 147
Viral Vectors for Gene Transfer
Chen, Y. H., Keiser, M. S., & Davidson, B. L. (2018) · Current Protocols in Mouse Biology · doi:10.1002/cpmo.58 · Cited by 146
AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression
Ding, K., Shen, J., Hafiz, Z., Hackett, S. F., Silva, R. L. E., Khan, M., Lorenc, V. E., Chen, D., Chadha, R., Zhang, M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129085 · Cited by 141
Rogers, G. L., Shirley, J. L., Zolotukhin, I., Kumar, S. R. P., Sherman, A., Perrin, G. Q., Hoffman, B. E., Srivastava, A., Basner-Tschakarjan, E., Wallet, M. A., et al. (2017) · Blood · doi:10.1182/blood-2016-11-751040 · Cited by 131
Gauvain, G., Akolkar, H., Chaffiol, A., Arcizet, F., Khoei, M. A., Desrosiers, M., Jaillard, C., Caplette, R., Marre, O., Bertin, S., et al. (2021) · Communications Biology · doi:10.1038/s42003-020-01594-w · Cited by 131
Gene therapy and genome surgery in the retina
DiCarlo, J. E., Mahajan, V. B., & Tsang, S. H. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120429 · Cited by 127
Gene therapy for RPE65-related retinal disease
Miraldi Utz, V., Coussa, R. G., Antaki, F., & Traboulsi, E. I. (2018) · Ophthalmic Genetics · doi:10.1080/13816810.2018.1533027 · Cited by 126
Seeing the light after 25 Years of retinal gene therapy
Trapani, I., & Auricchio, A. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.06.006 · Cited by 124
Self-citationOmichi, R., Shibata, S. B., Morton, C. C., & Smith, R. J. H. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz129 · Cited by 125
Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives
Bordet, T., & Behar-Cohen, F. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.05.038 · Cited by 120
Review of gene therapies for age-related macular degeneration
Khanani, A. M., Thomas, M. J., Aziz, A. A., Weng, C. Y., Danzig, C. J., Yiu, G., Kiss, S., Waheed, N. K., & Kaiser, P. K. (2022) · Eye · doi:10.1038/s41433-021-01842-1 · Cited by 119
Natural History of the Central Structural Abnormalities in Choroideremia
Alemán, T. S., Han, G., Serrano, L. W., Fuerst, N. M., Charlson, E. S., Pearson, D. J., Chung, D. C., Traband, A., Pan, W., Ying, G., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.10.022 · Cited by 119
Self-citationGene therapy for inherited retinal diseases: Progress and possibilities
Hu, M. L., Edwards, T. L., O’Hare, F., Hickey, D. G., Wang, J.-H., Liu, Z., & Ayton, L. N. (2021) · Clinical and Experimental Optometry · doi:10.1080/08164622.2021.1880863 · Cited by 118
Qi, B., He, L., Zhao, Y., Zhang, L., He, Y., Li, J., Li, C., Zhang, B., Huang, Q., Xing, J., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05103-w · Cited by 116
Challenges for Therapeutic Applications of Opsin-Based Optogenetic Tools in Humans
Shen, Y., Campbell, R. E., Côté, D. C., & Paquet, M.-È. (2020) · Frontiers in Neural Circuits · doi:10.3389/fncir.2020.00041 · Cited by 119
Small But Increasingly Mighty: Latest Advances in AAV Vector Research, Design, and Evolution
Grimm, D., & Büning, H. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.172 · Cited by 115
Retinal gene therapy: surgical vector delivery in the translation to clinical trials
Ochakovski, G. A., Bartz-Schmidt, K. U., & Fischer, M. D. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00174 · Cited by 110
Cell-based therapeutic strategies for replacement and preservation in retinal degenerative diseases
Jones, M. K., Lü, B., Girman, S., & Wang, S. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.01.004 · Cited by 114
Taking Stock of Retinal Gene Therapy: Looking Back and Moving Forward
Bennett, J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.008 · Cited by 117
Self-citationAll-in-one adeno-associated virus delivery and genome editing by Neisseria meningitidis Cas9 in vivo
Ibraheim, R., Song, C., Mir, A., Amrani, N., Xue, W., & Sontheimer, E. J. (2018) · Genome biology · doi:10.1186/s13059-018-1515-0 · Cited by 111
Engineering the AAV capsid to evade immune responses
Barnes, C., Scheideler, O. J., & Schaffer, D. V. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2019.01.002 · Cited by 109
Intravitreal, Subretinal, and Suprachoroidal Injections: Evolution of Microneedles for Drug Delivery
Hartman, R. R., & Kompella, U. B. (2017) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2017.0121 · Cited by 101
Gene therapy for visual loss: Opportunities and concerns
Lee, J. H., Wang, J.-H., Chen, J., Li, F., Edwards, T. L., Hewitt, A. W., & Liu, G. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.08.003 · Cited by 103
A look into retinal organoids: methods, analytical techniques, and applications
Afanasyeva, T. A. V., Corral-Serrano, J. C., Garanto, A., Roepman, R., Cheetham, M. E., & Collin, R. W. J. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03917-4 · Cited by 109
Chiu, W., Lin, T.-Y., Chang, Y.-C., Lai, H. I. A. M., Lin, S.-C., Ma, C., Yarmishyn, A. A., Lin, S.-C., Chang, K.-J., Chou, Y.-B., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094534 · Cited by 106
Ertl, H. C. J., & High, K. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.172 · Cited by 94
Self-citationCrossing the blood-brain barrier with AAV vectors
Liu, D., Zhu, M., Zhang, Y., & Diao, Y. (2020) · Metabolic Brain Disease · doi:10.1007/s11011-020-00630-2 · Cited by 98
Gene therapy for inherited retinal and optic nerve degenerations
Moore, N. A., Morral, N., Ciulla, T. A., & Bracha, P. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1389886 · Cited by 91
Clinical Perspectives and Trends: Microperimetry as a Trial Endpoint in Retinal Disease
Yang, Y., & Dunbar, H. (2021) · Ophthalmologica · doi:10.1159/000515148 · Cited by 93
T Cell-Mediated Immune Responses to AAV and AAV Vectors
Ertl, H. C. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.666666 · Cited by 88
Evaluating Efficiencies of Dual AAV Approaches for Retinal Targeting
Carvalho, L. S., Turunen, H. T., Wassmer, S. J., Luna-Velez, M. V., Xiao, R., Bennett, J., & Vandenberghe, L. H. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00503 · Cited by 86
Self-citationJohnson, S. J., Buessing, M. G., O’Connell, T., Pitluck, S., & Ciulla, T. A. (2019) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2019.2512 · Cited by 82
Zabaleta, N., Dai, W., Bhatt, U., Hérate, C., Maisonnasse, P., Chichester, J. A., Sanmiguel, J. C., Estelien, R., Michalson, K. T., Diop, C., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.08.002 · Cited by 88
Tao, Y., Huang, M., Shu, Y., Ruprecht, A., Wang, H., Tang, Y., Vandenberghe, L. H., Wang, Q., Gao, G., Kong, W., et al. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.120 · Cited by 81
Genetic characteristics and epidemiology of inherited retinal degeneration in Taiwan
Chen, T., Huang, D.-S., Lin, C., Yang, C., Yang, C., Wang, V. Y., Lin, J., Luo, A. C., Hu, F., & Chen, P. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00180-1 · Cited by 80
Gene therapy for inherited retinal diseases
Nuzbrokh, Y., Ragi, S. D., & Tsang, S. H. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4726 · Cited by 79
Development of retinal atrophy after subretinal gene therapy with voretigene neparvovec
Reichel, F. F., Seitz, I. P., Wozar, F., Dimopoulos, S., Jung, R., Kempf, M., Kohl, S., Kortüm, F. C., Ott, S., Pohl, L., et al. (2022) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2021-321023 · Cited by 79
Gene Therapy and Stem Cell Transplantation in Retinal Disease: The New Frontier
MacLaren, R. E., Bennett, J., & Schwartz, S. D. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.06.041 · Cited by 79
Self-citationRukmini, A. V., Miléa, D., & Gooley, J. J. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00076 · Cited by 79
Voretigene Neparvovec in Retinal Diseases: A Review of the Current Clinical Evidence
Gao, J., Hussain, R. M., & Weng, C. Y. (2020) · Clinical ophthalmology · doi:10.2147/opth.s231804 · Cited by 80
OPA1: How much do we know to approach therapy?
Dotto, V. D., Fogazza, M., Lenaers, G., Rugolo, M., Carelli, V., & Zanna, C. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.018 · Cited by 76
Varela, M. D., de Guimarães, T. A. C., Georgiou, M., & Michaelides, M. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-318483 · Cited by 74
Gene therapy for inherited retinal disease: Long-term durability of effect
Leroy, B. P., Fischer, M. D., Flannery, J. G., MacLaren, R. E., Dalkara, D., Scholl, H. P. N., Chung, D. C., Spera, C., Viriato, D., & Banhazi, J. (2023) · Ophthalmic Research · doi:10.1159/000526317 · Cited by 70
Self-citationAAV Capsid-Promoter Interactions Determine CNS Cell-Selective Gene Expression In Vivo
Powell, S., Samulski, R. J., & McCown, T. J. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.03.007 · Cited by 74
Emerging approaches for restoration of hearing and vision
Kleinlogel, S., Vogl, C., Jeschke, M., Neef, J., & Moser, T. (2020) · Physiological Reviews · doi:10.1152/physrev.00035.2019 · Cited by 74
The Effect of CpG Sequences on Capsid-Specific CD8+ T Cell Responses to AAV Vector Gene Transfer
Xiang, Z., Kurupati, R. K., Li, Y., Kuranda, K., Zhou, X., Mingozzi, F., High, K. A., & Ertl, H. C. J. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.014 · Cited by 67
Self-citationBritten‐Jones, A. C., Jin, R., Gocuk, S. A., Cichello, E., O’Hare, F., Hickey, D. G., Edwards, T. L., & Ayton, L. N. (2021) · Genetics in Medicine · doi:10.1016/j.gim.2021.10.013 · Cited by 67
Changes in Retinal Sensitivity after Gene Therapy in Choroideremia
Fischer, M. D., Ochakovski, G. A., Beier, B., Seitz, I. P., Vaheb, Y., Kortuem, C., Reichel, F. F. L., Kuehlewein, L., Kahle, N. A., Peters, T., et al. (2020) · Retina · doi:10.1097/iae.0000000000002360 · Cited by 66
Adeno-Associated Viral Gene Therapy for Inherited Retinal Disease
Ong, T., Pennesi, M. E., Birch, D. G., Lam, B. L., & Tsang, S. H. (2019) · Pharmaceutical Research · doi:10.1007/s11095-018-2564-5 · Cited by 66
Is Viral Vector Gene Delivery More Effective Using Biomaterials?
Wang, Y., Bruggeman, K. F., Franks, S. J., Gautam, V., Hodgetts, S. I., Harvey, A. R., Williams, R. J., & Nisbet, D. R. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202001238 · Cited by 69
Gene and cell‐based therapies for inherited retinal disorders: An update
Sengillo, J. D., Justus, S., Tsai, Y., Cabral, T., & Tsang, S. H. (2016) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31534 · Cited by 70
Gene editing and its applications in biomedicine
Li, G., Li, X., Zhuang, S., Wang, L., Zhu, Y., Chen, Y., Sun, W. C., Wu, Z., Zhou, Z. L., Chen, J., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-021-2057-0 · Cited by 66
Deng, C., Zhao, P. Y., Branham, K., Schlegel, D., Fahim, A. T., Jayasundera, T. K., Khan, N., & Besirli, C. G. (2022) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-021-05508-2 · Cited by 64
Efficient Gene Transfer to Kidney Mesenchymal Cells Using a Synthetic Adeno-Associated Viral Vector
Ikeda, Y., Sun, Z. Q., Xiao, R., Vandenberghe, L. H., & Humphreys, B. D. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018040426 · Cited by 65
Inherited retinal disease in Norway – a characterization of current clinical and genetic knowledge
Holtan, J. P., Selmer, K. K., Heimdal, K., & Bragadóttir, R. (2019) · Acta Ophthalmologica · doi:10.1111/aos.14218 · Cited by 64
Suprachoroidal gene transfer with nonviral nanoparticles
Shen, J., Kim, J., Tzeng, S. Y., Ding, K., Hafiz, Z., Long, D., Wang, J., Green, J. J., & Campochiaro, P. A. (2020) · Science Advances · doi:10.1126/sciadv.aba1606 · Cited by 63
Parker, M. A., Erker, L. R., Audo, I. S., Choi, D., Mohand‐Saïd, S., Šeštakauskas, K., Benoit, P., Appelqvist, T., Krahmer, M. R., Ségaut-Prévost, C., et al. (2022) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2022.02.013 · Cited by 61
Complexity of immune responses to AAV transgene products – Example of factor IX
Herzog, R. W. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.05.006 · Cited by 60
Formica, M. L., Alfonso, H. G. A., & Palma, S. D. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.723 · Cited by 60
Delivery Approaches for Therapeutic Genome Editing and Challenges
Ates, I., Rathbone, T., Stuart, C., Bridges, P. H., & Cottle, R. N. (2020) · Genes · doi:10.3390/genes11101113 · Cited by 63
Manufacturing Clinical Grade Recombinant Adeno-Associated Virus Using Invertebrate Cell Lines
Kotin, R. M., & Snyder, R. O. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.042 · Cited by 59
Ciulla, T. A., Hussain, R. M., Berrocal, A. M., & Nagiel, A. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1740676 · Cited by 59
Gene therapy in inherited retinal degenerative diseases, a review
Takahashi, V. K. L., Takiuti, J. T., Jauregui, R., & Tsang, S. H. (2018) · Ophthalmic Genetics · doi:10.1080/13816810.2018.1495745 · Cited by 61
RDH12 Mutations Cause a Severe Retinal Degeneration With Relatively Spared Rod Function
Alemán, T. S., Uyhazi, K. E., Serrano, L. W., Vasireddy, V., Bowman, S. J., Ammar, M. J., Pearson, D. J., Maguire, A. M., & Bennett, J. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-24708 · Cited by 59
Self-citationCost Utility of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease
Zimmermann, M. R., Lubinga, S. J., Banken, R., Rind, D. M., Cramer, G., Synnott, P. G., Chapman, R. H., Khan, S., & Carlson, J. J. (2018) · Value in Health · doi:10.1016/j.jval.2018.09.2841 · Cited by 58
Chien, Y., Hsiao, Y., Chou, S., Lin, T.-Y., Yarmishyn, A. A., Lai, W., Lee, M., Lin, Y., Lin, T.-W., Hwang, D., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01717-x · Cited by 59
Metadata
- Authors
- Bennett, J., Wellman, J., Marshall, K. A., McCague, S., Ashtari, M., DiStefano-Pappas, J., Elci, O. U., Chung, D. C., Sun, J., Wright, J. F., Cross, D. R., Aravand, P., Cyckowski, L. L., Bennicelli, J. L., Mingozzi, F., Auricchio, A., Pierce, E. A., Ruggiero, J., Leroy, B. P., Simonelli, F., High, K. A., & Maguire, A. M.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Spark Therapeutics (United States) (US)
- University of Pennsylvania (US)
- Federico II University Hospital (IT)
- Massachusetts Eye and Ear Infirmary (US)
- University of Campania "Luigi Vanvitelli" (IT)
- Corresponding author
- Bennett, Jean
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2016-08
- Volume
- 388
- Issue
- 10045
- Pages
- 661-672
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC5351775
- OpenAlex
- W2473832992
- Cited by
- 461
- References
- 29
- Citations by year
- 2026: 28 · 2025: 32 · 2024: 31 · 2023: 41 · 2022: 50 · 2021: 54 · 2020: 66 · 2019: 38 · 2018: 55 · 2017: 56 · 2016: 8
- FWCI
- 27.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (publishedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- FWO Flanders (grant OZP 3G004306)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- RPE65 mutations, inherited retinal disease, subretinal gene therapy, recombinant adeno-associated virus vectors, immune response, visual function, mobility, visual cortex activation, pediatric patients
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Adolescent, Adult, Blindness, Child, Female, Follow-Up Studies, Genetic Vectors, Humans, Male, Middle Aged, Mutation, Occipital Lobe, Vision, Ocular, Genetic Therapy, Linear Models, Age of Onset, Retinal Rod Photoreceptor Cells, Retinal Cone Photoreceptor Cells, Retreatment, Evidence-Based Medicine, cis-trans-Isomerases, Injections, Intraocular, Administration, Ophthalmic, Patient Safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
